- Home
- LSTA vs VYNE Comparison
LSTA vs VYNE Comparison
Compare LSTA & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | VYNE |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 19.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LSTA | VYNE |
|---|---|---|
| Price | $4.56 | $0.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 395.2K | ★ 418.2K |
| Earning Date | 02-27-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $1.81 | $0.28 |
| 52 Week High | $4.89 | $2.94 |
Technical Indicators
Market Signals| Indicator | LSTA | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 78.30 | 67.70 |
| Support Level | $4.51 | $0.55 |
| Resistance Level | $4.62 | $0.57 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 29.51 | 82.94 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.